Unity Biotechnology

What it is

Unity Biotechnology was founded in 2011 by Judith Campisi, Nathaniel David, and others as the first dedicated senolytic company. IPO’d in 2018 with significant attention; subsequently restructured following unexpected disappointments in early systemic senolytic trials.

Pivot

The original osteoarthritis-knee programme (UBX0101) failed in Phase 2. Unity pivoted to intravitreal (eye-injected) senolytics for diabetic macular edema and neovascular AMD:

• UBX1325 (foselutoclax) — a BCL-xL inhibitor delivered locally to the retina, where systemic toxicity is avoided.
• Phase 2 results showed visual-acuity improvements with extended durability, encouraging further development.

Why it matters

• Validates the principle that local senolytic delivery can sidestep the haematological toxicity of BCL-family inhibitors that limits systemic dosing.
• Demonstrates the long, hard road from senescence biology to clinically useful medicine, in contrast to over-promising consumer narratives.

Related entries

Cellular senescence, Senolytics, Age-related macular degeneration, Judith Campisi.